The European Commission has approved epcoritamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma.
|Videos|March 14, 2011
Dr. Siegel on the Practice Changes the Past 10 Years
Author(s)David S. Siegel, MD, PhD
David S. Siegel, MD, PhD, Chief, Multiple Myeloma at John Theurer Cancer Center, on how his practice has changed over the past 10 years.
Advertisement
David S. Siegel, MD, PhD, Chief, Multiple Myeloma at John Theurer Cancer Center, on how his practice has changed over the past 10 years.
Advertisement
Related to this article
The FDA approved Orca-T, issued a CRL to a NET imaging agent, and more.
The FDA approved Orca-T for use in matched donor HSCT with a myeloablative preparative regimen in hematological malignancies.
Both annamycin-containing arms produced numerically higher CR and CRc rates vs cytarabine alone in relapsed/refractory AML.
Romiplostim N01 supported platelet engraftment after unrelated umbilical cord blood transplantation with no serious TRAEs in hematologic malignancies.
The top 5 OncLive TV videos of the week cover insights in breast cancer, lymphoma, melanoma, prostate cancer, and ovarian cancer.
IV ST-001 nanoFenretinide produced a 28% response rate in heavily pretreated cutaneous T-cell lymphoma in a first-in-human phase 1a trial.
In an MAIC, mogamulizumab led to an OS improvement vs vorinostat in patients with relapsed/refractory mycosis fungoides or Sézary syndrome.
Advertisement
Advertisement
Trending on OncLive
1
TP53 Status and Time Toxicity Shape Sequencing Decisions in EGFR-Mutated NSCLC
2
Divarasib Outperforms First-Generation KRAS G12C Inhibitors in Phase 3 NSCLC Trial
3
Savolitinib Gains NMPA Approval for MET-Amplified Gastric and GEJ Adenocarcinoma
4
Rusfertide Maintains Long-Term Thromboembolism Control in Phlebotomy-Dependent Polycythemia Vera
5